Mitiglinide
Chemical compound
- A10BX08 (WHO)
- (−)-(2S,3a,7a-cis)-α-Benzylhexahydro-γ-oxo-2-isoindolinebutyric acid
- 145375-43-5
N
- 121891
- DB01252
Y
- 108739 Y
- D86I0XLB13
- D01854 Y
- ChEMBL471498 Y
- DTXSID4048303
- Interactive image
- O=C(O)[C@@H](Cc1ccccc1)CC(=O)N3C[C@H]2CCCC[C@H]2C3
InChI
- InChI=1S/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23)/t15-,16+,17-/m0/s1Y
- Key:WPGGHFDDFPHPOB-BBWFWOEESA-NY
N
Y (what is this?) (verify)Mitiglinide (INN,[1] trade name Glufast) is a drug for the treatment of type 2 diabetes.[2]
Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.
Pharmacology
Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive potassium KATP channels in pancreatic β cells.
Dosage
Mitiglinide is delivered in tablet form.
References
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names (Rec. INN): List 40" (PDF). World Health Organization. p. 187. Retrieved 10 November 2016.
- ^ Malaisse WJ (October 2008). "Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients". Expert Opinion on Pharmacotherapy. 9 (15): 2691–8. doi:10.1517/14656566.9.15.2691. PMID 18803455. S2CID 73318104.
External links
- Elixir Pharmaceuticals — website of the U.S. rights holder for mitiglinide.
- v
- t
- e
| |||||||||||
